Sun Pharma receives DCGI approval for Noveltreat, a generic semaglutide injection for chronic weight management in adults, supported by Phase III trial data in India.
Written By: Pharmacally Medical News Desk
Sun Pharmaceutical Industries Limited has received approval from the Drug Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection for chronic weight management in adults. The therapy is indicated as an adjunct to a reduced-calorie diet and increased physical activity.
Commenting on the approval, Kirti Ganorkar, Managing Director of Sun Pharma, said that obesity and diabetes are among the most pressing health challenges in the country. He added that GLP-1–based therapies can play a meaningful role in tackling this burden and emphasized the company’s commitment to improving access to generic semaglutide across India after patent expiry.
Product and launch details
Sun Pharma plans to launch the generic semaglutide injection under the brand name Noveltreat following the expiry of the semaglutide patent in India. The DCGI approval was granted after reviewing data from a Phase III clinical trial conducted in India, supporting the product’s efficacy and safety for weight management.
Noveltreat will be available in five dose strengths:
- 0.25 mg/0.5 mL
- 0.5 mg/0.5 mL
- 1 mg/0.5 mL
- 1.7 mg/0.75 mL
- 2.4 mg/0.75 mL
The recommended maintenance dose is 2.4 mg once weekly. The medicine is administered using a prefilled, easy-to-use pen designed to enable accurate and convenient dosing.
Addressing India’s cardiometabolic burden
Semaglutide belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which have become an important option for managing obesity and related metabolic conditions. With obesity and diabetes rising steadily in India, wider access to evidence-backed therapies is seen as a key public health priority.
Dr. Unnikrishnan A G, Chief Endocrinologist and CEO of the Chellaram Diabetes Institute, highlighted that GLP-1 receptor agonists such as semaglutide represent an important scientific advancement for overall metabolic health, not just weight reduction. He noted that these therapies should be used alongside lifestyle measures like diet and physical activity and under close medical supervision, adding that improved accessibility could help address significant unmet patient needs.
In a related development, Sun Pharma had already received DCGI approval in December 2025 to manufacture and market semaglutide injection for adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. That product will be launched under the brand name Sematrinity, also after the expiry of the semaglutide patent in India.
References
Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management, 23 January 2026, https://sunpharma.com/wp-content/uploads/2026/01/PR-SEMAGLUTIDE-DCGI-APPROVAL.pdf